The deal also includes a long-term agreement for Agilera to supply lutetium Lu 177 dotatate to Lantheus, PharmaLogic said Monday. Financial terms were not disclosed.

PharmaLogic, a radiopharmaceutical CDMO company, said the acquisition will make it the first therapeutic CDMO to offer a transatlantic platform. Chief Executive Officer Etienne Montagut said it would strengthen Agilera’s capabilities in radioligand therapies and expand its U.S. capacity.